

MATTIA POZZATO

Date of birth:

E-mail:

Phone:

Address:



Role and education

Residency in Neurology University of Milan

November 2018-on going

- From 1 november 2019 at IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico di Milano.
- From 1 november 2018 to 31 october 2019 at IRCCS Policlinico San Donato

Graduation in Medicine and Surgery - 110L/110 Università Vita e Salute San Raffaele

2011-2017

High school diploma Liceo Scientifico Carlo Alberto, Novara.

2006-2011

Professional experiences

Emergency Medicine Service, Novara

April 2018-on going

Temporary Doctor of General Medicine

2018

- Vimodrone (Milano)
- Magenta (Milano)

Fellowship at San Raffaele Hospital, Milan

November 2017 - January 2018

- Oncohematology Unit (Director Prof. Fabio Ciceri)
- Orthopedic Surgery Unit (Director Prof. Gianfranco Fraschini)
- General Medicine (Dott. Carmelo Partenope)

Fellowship at San Raffaele Hospital, Milan

2016-2017

Neurology Unit (Director Prof. Giancarlo Comi): activity in Stroke Unit Department, Multiple Sclerosis Department and Pediatric Neurology Department. Working at thesis project "*Inflammatory cells and their by-products are key components of arterial thrombi retrieved in acute cerebral ischemia*".

Fellowship at San Raffaele Hospital, Milan

2015

Hematology Unit (Director Prof. Fabio Ciceri).

Research activities

Sub-investigator of the CLADFIT-MS study

2021-on going

An observational, multicenter, prospective, phase IV study evaluating cladribine tablets' effects on PROs and their correlation with clinical and biometric parameters using Health Technology in subjects with highly-active RMS at their first switch.

Sub-investigator of the FenHance study 2021-on going
A phase III multicenter, randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of fenebrutinib compared with teriflunomide in adult patients with relapsing multiple sclerosis.

Sub-investigator of the MUSETTE study 2021-on going
A phase IIIb multicenter, randomized, double-blind, controlled study to evaluate the efficacy, safety and pharmacokinetics of a higher dose of ocrelizumab in adults with relapsing multiple sclerosis.

Member of the PEDIGREE study 2020-on going
Identification of genetic risk factors and interaction between genetic and non-genetic risk factors in pediatric multiple sclerosis (PEDiatric Italian Genetic and environment ExsposurE).

Member of the MuSC-19 study 2020-on going
Multiple Sclerosis and Covid-19

Sub-investigator of the MuSicalE study 2019-on going
A multicentre non-interventional study to assess the real-world effectiveness of Ocrelizumab in patients with relapsing or primary progressive multiple sclerosis.

Fellowship at Istituto di Neurologia Sperimentale (INSPE) 2016-2017
Università Vita e Salute San Raffaele, Milan
Director Prof. Gianvito Martino.

Training courses and conferences

51° SIN (Italian Society of Neurology) meeting, <i>virtual</i> .	2020
6° EAN (European Academy of Neurology) meeting, <i>virtual</i> .	2020
50° SIN (Italian Society of Neurology) meeting, Bologna.	2019
Investigator Meeting – MUSICALE, Frankfurt.	2019
BLS-D (Basic Life Support and Defibrillator), Italian Resuscitation Council, Milan.	2017
OSR Scientific Retreat, Baveno (Novara).	2017
Neurological emergencies meeting, Milan.	2017

Skills

BLS-D (Basic Life Support and Defibrillator).
Clinical activity in medicine wards.
Day-hospital activities.
Ambulatorial activities.
Basic surgery activities.
Speech: italian (mother tongue), english.

Congress presentations and posters

51° SIN meeting, virtual. 2020
Oral presentation “The spectrum of CNS inflammatory demyelinating disease in children: an unusual case report of Neuro-Behçet’s disease occurring at 2 years?”.

6° EAN meeting, virtual.

2020

Poster presentation “*A case-control study of environmental risk factors in an Italian cohort of Multiple Sclerosis patients*”.

50° SIN meeting, Bologna.

2019

Posters presentation “*A case of co-occurrence of Familial Mediterranean Fever and Multiple Sclerosis: which is the best drug?*”, and “*Patient affected by intermittent hemiplegia due to unihemispheric Primary Central Nervous System Vasculitis: a diagnostic challenge*”.

OSR Scientific Retreat, Baveno (Novara).

2017

Poster presentation “*Inflammatory cells as key components in thrombus composition and lysis susceptibility*”.

Publications

Carandini T, Pietroboni AM, Sacchi L, **Pozzato M**, et al. Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression. *Mult Scler.* 2020;26(10):1268-1269. doi:10.1177/1352458520926459

Pozzato M, Micaglio E, Starvaggi Cucuzza C, et al. Case Report: Efficacy of Rituximab in a Patient With Familial Mediterranean Fever and Multiple Sclerosis. *Front Neurol.* 2020;11:591395. doi:10.3389/fneur.2020.591395

Carandini T, **Pozzato M**, Scola E, Avignone S, Pietroboni AM. Osmotic demyelination syndrome and leukoencephalopathy in FGF23-related hypophosphatemia: a case report. *Neurol Sci.* Published online January 7, 2021. doi:10.1007/s10072-020-04952-y

Colombo A, Martinelli Boneschi F, Beretta S, **Pozzato M**, et al. Posterior reversible encephalopathy syndrome and COVID-19: A series of 6 cases from Lombardy, Italy. *eNeurologicalSci.* 2021;22:100306. doi:10.1016/j.ensci.2020.100306

Pietroboni AM, Lanfranconi S, Novella A, **Pozzato M**, et al. Clinical features and disease course of patients with acute ischaemic stroke just before the Italian index case: Was COVID-19 already there? *Intern Emerg Med.* Published online February 10, 2021. doi:10.1007/s11739-021-02634-x

Sormani MP, De Rossi N, Schiavetti I, and the **Musc-19 Study Group**. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. *Ann Neurol.* Published online January 21, 2021. doi:10.1002/ana.26028

Genchi A, Semerano A, Gullotta GS, **Pozzato M**, et al. Cerebral thrombi of cardioembolic etiology have an increased content of neutrophil extracellular traps. *J Neurol Sci.* 2021;423:117355. doi:[10.1016/j.jns.2021.117355](https://doi.org/10.1016/j.jns.2021.117355)



“In compliance with the Italian legislative Decree no. 196 dated 30/06/2003, I hereby authorize you to use and process my personal details contained in this document.”